Calidi Biotherapeutics
CLDI
24 hedge funds and large institutions have $39M invested in Calidi Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.05% → 0.05% (-0%)
4% less capital invested
Capital invested by funds: $40.6M → $39M (-$1.62M)
8% less funds holding
Funds holding: 26 → 24 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$2.21M |
| 2 |
QL
Quarry LP
New York
|
+$1.65M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$457K |
| 4 |
ASM
ATW SPAC Management
New York
|
+$437K |
| 5 |
CCM
CAAS Capital Management
New York
|
+$19.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$3.85M |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$2.07M |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$676K |
| 4 |
VF
Virtu Financial
New York
|
-$312K |
| 5 |
E
Ergoteles
New York
|
-$196K |
CLDI Hedge Fund Activity: Q2 2023 in Review
24 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q2 2023, worth a combined $39M — down 4% from $40.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLDI and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Clear Street, adding an estimated $2.21M. The largest seller was Glazer Capital LLC, exiting entirely with an estimated $3.85M sold.
- 24 institutional investors held Calidi Biotherapeutics (CLDI) as of Q2 2023, down from 26 in Q1 2023.
- Funds reported $39M of Calidi Biotherapeutics stock for Q2 2023, down 4% quarter-over-quarter.
- 3 funds opened new Calidi Biotherapeutics positions in Q2 2023 and 5 closed out, a net change of -2 holders.
- The largest Calidi Biotherapeutics buyer in Q2 2023 was Clear Street, an estimated $2.21M added.
- The largest Calidi Biotherapeutics seller in Q2 2023 was Glazer Capital LLC, an estimated $3.85M sold.
Based on aggregated 13F filings for Q2 2023.